By Connor Hart
Shares of Fulgent Genetics climbed after the company raised its outlook as it posted higher-than-expected earnings and revenue in the second quarter.
The stock jumped 15%, to $19.75, in premarket trading Friday. Through Thursday's close, shares have lost nearly one-third of their value in the past year.
The company, which runs both laboratory services and therapeutic development businesses, before the bell posted a loss of $19 million, or 62 cents a share, compared with a loss of $8.7 million, or 29 cents a share, a year earlier.
Adjusted earnings came in at 7 cents a share. Analysts surveyed by FactSet had expected an adjusted loss of 18 cents a share.
Revenue rose 15% to $81.8 million, topping the $76.2 million that Wall Street modeled.
For the year, Fulgent raised its revenue guidance by $10 million, to approximately $320 million. The El Monte, Calif., company now expects to post an adjusted loss of about 35 cents a share, compared with a prior outlook of about 65 cents a share.
Analysts are looking for an adjusted loss of 55 cents a share on revenue of $310.7 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 01, 2025 09:00 ET (13:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。